%0 Journal Article %1 Doll2001 %A Doll, B. %A Sfeir, C. %A Winn, S. %A Huard, J. %A Hollinger, J. %D 2001 %J Crit Rev Eukaryot Gene Expr %K & *Bone *Tissue *Transforming ; Animals Biopolymers/therapeutic Bone Carriers Cell Cells, Collagen/administration Cultured/transplantation Delivery Diseases/*therapy Dogs Drug Engineering Evaluation, Factor Fusion Gene Growth Haplorhini Humans Knockout Materials Mice Mice, Microspheres Morphogenetic Osteoblasts/drug Osteoclasts/drug Preclinical Proteins Proteins/genetics/therapeutic Proteins/therapeutic Rabbits Rats Recombinant Regeneration/drug Sheep Signal Stem Substances/administration Substitutes/*therapeutic Swine Systems Testing Therapy Transduction/drug Transgenic Transplantation beta dosage dosage/genetics/*therapeutic effects effects/physiology use %N 1-3 %P 173-98 %T Critical aspects of tissue-engineered therapy for bone regeneration. %U http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?cmd=prlinks&dbfrom=pubmed&retmode=ref&id=11693960 %V 11 %X Recent advances in bone tissue engineering are established on the understanding of an engineered scaffold, the molecular milieu within the osteogenic site, and the cell(s) predisposed to an osteogenic lineage. Advances in the incorporation of a generative vehicle into a skeletal defect require temporal and spatial distribution of the scaffold, growth factor, and cell compatible with enhanced bone healing. Monitoring events culminating in osteogenesis has focused on phenotypic and intracellular indicators. Phenotypic and intracellular indicators include the presence of receptors and intracellular signals that enable cell proliferation and differentiation. Progress in the areas of scaffold design, growth factor utilization, bone cell lineage, and intracellular signaling are reviewed.

@article{Doll2001, __markedentry = {[phpts:6]}, abstract = {Recent advances in bone tissue engineering are established on the understanding of an engineered scaffold, the molecular milieu within the osteogenic site, and the cell(s) predisposed to an osteogenic lineage. Advances in the incorporation of a generative vehicle into a skeletal defect require temporal and spatial distribution of the scaffold, growth factor, and cell compatible with enhanced bone healing. Monitoring events culminating in osteogenesis has focused on phenotypic and intracellular indicators. Phenotypic and intracellular indicators include the presence of receptors and intracellular signals that enable cell proliferation and differentiation. Progress in the areas of scaffold design, growth factor utilization, bone cell lineage, and intracellular signaling are reviewed.}, added-at = {2011-11-04T13:47:04.000+0100}, author = {Doll, B. and Sfeir, C. and Winn, S. and Huard, J. and Hollinger, J.}, authoraddress = {Carnegie Mellon University, Bone Tissue Engineering Center, Pittsburgh, PA 15213-3890, USA. bdoll@cs.cmu.edu}, biburl = {https://www.bibsonomy.org/bibtex/2c50917850facadb5b4a6e88c405b2f9b/pawelsikorski}, interhash = {72e80a84c6365336a0902b768bf7ce07}, intrahash = {c50917850facadb5b4a6e88c405b2f9b}, journal = {Crit Rev Eukaryot Gene Expr}, keywords = {& *Bone *Tissue *Transforming ; Animals Biopolymers/therapeutic Bone Carriers Cell Cells, Collagen/administration Cultured/transplantation Delivery Diseases/*therapy Dogs Drug Engineering Evaluation, Factor Fusion Gene Growth Haplorhini Humans Knockout Materials Mice Mice, Microspheres Morphogenetic Osteoblasts/drug Osteoclasts/drug Preclinical Proteins Proteins/genetics/therapeutic Proteins/therapeutic Rabbits Rats Recombinant Regeneration/drug Sheep Signal Stem Substances/administration Substitutes/*therapeutic Swine Systems Testing Therapy Transduction/drug Transgenic Transplantation beta dosage dosage/genetics/*therapeutic effects effects/physiology use}, language = {eng}, medline-da = {20011105}, medline-dcom = {20020408}, medline-edat = {2001/11/06 10:00}, medline-fau = {Doll, B ; Sfeir, C ; Winn, S ; Huard, J ; Hollinger, J}, medline-is = {1045-4403 (Print)}, medline-jid = {9007261}, medline-jt = {Critical reviews in eukaryotic gene expression.}, medline-lr = {20051117}, medline-mhda = {2002/04/09 10:01}, medline-own = {NLM}, medline-pl = {United States}, medline-pmid = {11693960}, medline-pst = {ppublish}, medline-pt = {Journal Article ; Review}, medline-pubm = {Print}, medline-rf = {214}, medline-rn = {0 (BMP2 protein, human) ; 0 (Biopolymers) ; 0 (Bmp2 protein, mouse) ; 0 (Bmp2 protein, rat) ; 0 (Bone Morphogenetic Proteins) ; 0 (Bone Substitutes) ; 0 (Drug Carriers) ; 0 (Growth Substances) ; 0 (Recombinant Fusion Proteins) ; 0 (Recombinant Proteins) ; 0 (Transforming Growth Factor beta) ; 0 (bone morphogenetic protein 2) ; 0 (recombinant human bone morphogenetic protein-2) ; 9007-34-5 (Collagen)}, medline-sb = {IM}, medline-so = {Crit Rev Eukaryot Gene Expr. 2001;11(1-3):173-98.}, medline-stat = {MEDLINE}, number = {1-3}, owner = {phpts}, pages = {173-98}, timestamp = {2011-11-04T13:47:08.000+0100}, title = {Critical aspects of tissue-engineered therapy for bone regeneration.}, url = {http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?cmd=prlinks\&dbfrom=pubmed\&retmode=ref\&id=11693960}, volume = 11, year = 2001 }